Wegovy 2.7 mg: Is This the Right Dose for Where You Are in Treatment?

Why 2.7 mg does not appear on any licensed Wegovy pen

The Wegovy titration ladder has six distinct steps. Starting at 0.25 mg, the schedule moves through 0.5 mg, then 1.0 mg, 1.7 mg, and 2.4 mg, each step separated by roughly four weeks. The jump from 1.7 mg to 2.4 mg is the largest single increase in the schedule, and it is the point where some patients notice a meaningful shift in how the medicine works for them. There is no 2.7 mg pen because the licensed Wegovy mg strengths were set through the clinical trial programme on which the MHRA based its approval; the doses chosen were those shown to balance efficacy and tolerability across the study population.

If you have encountered a reference to 2.7 mg online, it is worth spending a minute checking the source. A quick look at the NHS semaglutide medicines page lists the authorised strengths clearly. Any seller advertising a 2.7 mg Wegovy product is either describing a different medicine or, more worryingly, a product that has not been licensed by the MHRA. The MHRA has warned publicly about counterfeit weight-loss pens entering the UK market; unlicensed products have no verified ingredient or dose accuracy. That check takes about thirty seconds and could save you from a serious mistake.

For a fuller picture of how the complete schedule is structured and why each step exists, the Wegovy dose guide walks through each transition in plain detail.

The decision your prescriber is really making at each dose increase

The framing of "which dose am I on" is natural, but it slightly misses the point. The decision a prescriber is actually making at each review is whether the benefit you are getting justifies moving to a higher exposure, and whether your body is tolerating the current dose well enough for that to be safe. Nausea, diarrhoea, and appetite suppression all tend to be most noticeable shortly after a dose increase, then settle over the following weeks. If those effects have not settled by the time your next review comes around, staying at the current dose for longer is a legitimate clinical choice, not a failure.

At 1.7 mg specifically (the step immediately before the standard maintenance dose) many people find the medicine's effect on appetite starts to feel more consistent. That does not mean 2.4 mg will feel dramatically different; for some it does, for others the shift is subtle. What matters is that the decision is made with someone who can look at your weight trend, your side-effect history, and any other medicines you take. Oral contraceptives, for instance, may be less reliably absorbed during the early weeks of semaglutide treatment and after each dose increase, so your prescriber needs the full picture before signing off any change. The NHS England guidance on weight management injections covers this interaction point in detail.

If you want to understand what the Wegovy 1 mg step feels like for most people before moving to maintenance dose, the 1.7 mg page covers it specifically.

Where the schedule goes beyond 2.4 mg, and whether it changes things

The approval of a 7.2 mg Wegovy dose is a meaningful development in the UK licensing picture. The MHRA approved a dedicated single-dose 7.2 mg pen on 14 April 2026, designed for adults with a BMI of 30 or above. Trial data at this higher dose reported around 20.7% average weight loss over 72 weeks, which narrows the gap with tirzepatide results seen in the SURMOUNT programme. That said, 7.2 mg is the maximum dose, not the starting point, and not appropriate for everyone. You still begin at 0.25 mg and work up through the standard schedule before any consideration of moving beyond 2.4 mg, and that clinical assessment applies each time.

For anyone considering the cost side of treatment as their schedule progresses, the Wegovy price comparison page sets out how pricing tends to vary across providers and doses. The dose increase conversation is worth having with a prescriber who has reviewed your history, not with a checkout page. If you are exploring what Wegovy treatment looks like more broadly, our Wegovy overview covers eligibility, how it works, and what ongoing clinical support involves.

At the end of the titration process, the goal is reaching the dose that is both effective for you and tolerable. That is a clinical judgement. Our prescribers at nume review each dose change individually, no automated approvals, no assumptions carried forward from a previous order. If you would like a clinician to assess where you are in your treatment and whether your current dose is right, speaking to our prescribers is the straightforward next step.